Optimization of pyrrolidinone based HIV protease inhibitors.
Bioorganic & medicinal chemistry letters 2005 Jan 3; 15(1):81-4
Sherrill R RG, Andrews C CW, Bock W WJ, Davis-Ward R RG, Furfine E ES, Hazen R RJ, Rutkowske R RD, Spaltenstein A A, Wright L LL
GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA. ron.g.sherrill@gsk.com
Optimization of P1-substituted pyrrolidinone based HIV protease inhibitors has yielded analogs with very potent antiviral activity.

